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Abstract 
Fronto-limbic white matter (WM) abnormalities are assumed to lie at the heart of the 
pathophysiology of bipolar disorder (BD); however, diffusion tensor imaging (DTI) studies 
have reported heterogeneous results and it is not clear how the clinical heterogeneity is 
related to the observed differences. This study aimed to      identify      WM abnormalities that 
differentiate patients with BD from healthy controls (HC) in the largest DTI dataset of 
patients with BD to date, collected via the ENIGMA network. We gathered individual tensor-
derived regional metrics from 26 cohorts leading to a sample size of N = 3,033 (1,482 BD 
and 1,551 HC). Mean fractional anisotropy (FA) from 43 regions of interest (ROI) and 
average whole-brain FA were entered into univariate mega- and meta-analyses to 
differentiate patients with BD from HC.  Mega-analysis revealed significantly lower FA in 
patients with BD compared with HC in 29 regions, with the highest effect sizes observed 
within the corpus callosum (R2 = 0.041, Pcorr < 0.001) and cingulum (right: R2 = 0.041, left: 
R2 = 0.040, Pcorr < 0.001). Lithium medication, later onset and short disease duration were 
related to higher FA along multiple ROIs. Results of the meta-analysis showed similar 
effects. We demonstrated widespread WM abnormalities in BD and highlighted that altered 
WM connectivity within the corpus callosum and the cingulum are strongly associated with 
BD. These brain abnormalities could represent a      biomarker for use in the diagnosis      of 
BD.  
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Introduction 
Bipolar disorder (BD) is a severe chronic mental illness that affects approximately 1% of the 
general population [1]. There is often a long period with inadequate treatment before the 
diagnosis is established [2]. Consequently, there is a great need to identify biomarkers of BD. 
A better understanding of the neurobiology of BD could help to refine the diagnosis and 
guide innovative interventions. Recent advances in magnetic resonance imaging (MRI) could 
help to achieve this goal. 
Neural models of BD suggest a role of fronto-limbic dysconnectivity in the emergence of 
mood symptoms of BD [3,4]. This model is mainly supported by results from functional MRI 
(fMRI) studies demonstrating that emotional instability in this disorder might be underpinned 
by abnormal connectivity between frontal and limbic regions [5,6]. However, results from 
diffusion tensor imaging (DTI) studies, a technique that allows the exploration of structural 
connectivity in vivo, have highlighted far more extensive brain abnormalities in BD. Indeed, 
the first DTI studies identified alterations in limbic tracts [7-9], followed by numerous studies 
that reported WM alterations within non-limbic regions, such as the corpus callosum [10-15] 
and corona radiata [16]. Meta-analyses based on whole-brain data have revealed lower      
fractional anisotropy (FA), a metric derived from DTI known to be positively correlated with 
the directionality and coherence of white matter bundles [17], in patients with BD near the 
parahippocampal gyrus, subgenual cingulate cortex [18],      temporo-parietal junction and 
cingulum [19].  
Inconsistencies in the      location of WM microstructure alterations may be related to limited 
sample sizes and      diversity in methods to collect data from different      populations and for 
DTI data analysis. Indeed, differences in sample characteristics such as age of onset, disease 
duration, psychotic features and lithium treatment, all of which have been associated with 
WM features [12,20-22], may have contributed to the inconsistency in      previous findings.  
8 
Consequently, large harmonized multi-center studies are required to improve the reliability of 
case-control findings. 
The ENIGMA consortium presents a framework to identify generalizable biomarkers, by 
analyzing           large samples with      a harmonized processing pipeline - a strategy that has 
already identified widespread cortical alterations and specific subcortical volumetric 
abnormalities in patients with BD [23,24]. Thus, we analyzed DTI data from the ENIGMA-
BD working group with the objectives of i) identifying reliable generalizable WM 
abnormalities in BD using mega- and meta- analytics; ii) testing if clinical characteristics 
modulate WM microstructure using mega- analytics. Specifically     , we expected more 
pronounced alterations in WM microstructure in patients with a more severe course of illness, 
and a significant association with psychotropic medication. 
 
Methods  
Samples 
The ENIGMA-BD DTI working group, comprised of 26 cohorts spanning 12 countries, 
yielded a total of 3,033 individuals (1,551 healthy controls (HC) and 1,482 patients with BD) 
included in this study. Demographic and clinical information from the whole sample is shown 
in Table 1; details of the contributing sites may      be found in Table S1 and available clinical 
data for each site is provided in Table S2.      Each cohort comprised a minimum of 12 
subjects per group and a minimal ratio of patients to      controls of 1:3, to allow for robust 
comparisons and meta-analysis. When needed, we randomly removed some subjects from a 
given group (mainly control subjects that were too numerous at      4 sites, except for one site 
that comprised too many patients in comparison to controls;      for      details, see      Table 
S3). The current analysis includes data acquired until February 2018.  
9 
All participating sites obtained approval from their local ethics committees and all 
participants gave written informed consent. Participants younger than 18 or older than 65 as 
well as individuals with diffusion images with low quality after visual inspection (e.g., 
movement artifacts) were excluded from the analyses.  
**** INSERT TABLE 1 HERE **** 
Image processing 
Acquisition parameters for each of the 26 sites are provided in Table S4. The pre-processing 
(i.e., eddy current and echo-planar corrections and tensor fitting) was performed at each site 
using harmonized analysis and quality control protocols from the ENIGMA consortium that 
have previously been applied in large-scale studies of schizophrenia [25]; recommended 
pipelines and procedures for the image analyses and quality control are provided online at      
the ENIGMA-DTI website (http://enigma.ini.usc.edu/protocols/dti-protocols/). After 
estimation of tensors, each site performed the image analysis and extracted the FA of each 
region of interest (ROI) (see description in Table S5) according to the ENIGMA-DTI 
protocol. The multi-subject JHU white matter parcellation atlas [26] was used to parcellate 
regions of interest from the ENIGMA template in MNI space. Mean FA from 43 regions of 
interest (ROI) as well as average whole-brain FA were then extracted for each participant 
across all cohorts.  
Mega-analysis 
Our first aim was to identify WM microstructure differences between patients with BD and 
HC. We merged individual FA values of the 43 ROIs and Average FA (from each cohort) 
into one mega-analysis and entered them separately in a linear mixed model (using R 
software version 3.2.1. (R Core Team, 2015) and lme4 package [27]) including fixed effects 
for the diagnosis (patients vs. controls), age, sex and random intercepts for each site: 
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FA ROIi = Intercept + β1*Diagnosis + β2*Age + β3*Sex + random effect (site) 
We used Bonferroni correction to control for multiple comparisons (p < 0.05/44 = 0.0011). 
We also assessed the influence of average FA (per subject) across the entire TBSS FA tract 
skeleton (including core and periphery FA [25]) on local FA differences observed in the first 
analysis by running the same models including average FA as a covariate.  
We performed additional analyses to assess how age, sex, illness duration, age of onset, 
medication at the time of scan (lithium, antipsychotics, anticonvulsants, antidepressants), 
illness severity, history of psychotic symptoms and type of BD (type I vs. type II) might have 
modulated the main effect of diagnosis. We tested the effect of age and sex by including age-
by-diagnosis and sex-by-diagnosis interaction terms. We included medication and history of 
psychosis as dichotomous measures in the analyses (yes/no variables) and used the density of 
episodes as an index of illness severity (number of mood episodes/illness duration). 
Importantly, each analysis controlled for age and sex, so that associations with illness 
duration and the age of onset would not be confounded by global age differences.  
Age, sex and diagnosis were available for all      participants, whereas the remaining variables 
were available for some sites only (see Table S2 for details of available data for each site).  
Meta-analysis 
Given previous demonstrations of the usefulness of meta-analysis for multisite neuroimaging 
[28], we performed a meta-analysis to allow comparisons with previous ENIGMA studies 
and comparison across      sites. Similarly to previous ENIGMA meta-analyses, we conducted 
a random-effects inverse-variance weighted meta-analysis (R, metaphore package), to 
combine Cohen’s d effect size of each of the 26 cohorts of the study, both for right and left 
tracts separately and for bilateral tracts (to allow comparison with other ENIGMA DTI 
working groups). We calculated the I2 statistic to estimate the heterogeneity of the diagnostic 
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effects across sites. This analysis was run following publicly available scripts on the 
ENIGMA-GitHub (https://github.com/ENIGMA-git). 
Results 
We included 1,482 patients with BD and 1,551 HC. The patients were significantly older than 
the controls (mean age BD = 39.6 years; mean age HC = 35.1 years; t = 10.11; p < 0.001) and 
comprised a higher proportion of females (60.7% vs. 51.1%; Chi^2 = 25.77; p < 0.001). We 
included both age and sex as covariates in the mega- and meta-analyses, and tested for the 
age-by-diagnosis and sex-by-diagnosis interactions for further exploration of these effects.  
Mega-analysis 
Linear mixed models revealed significantly lower FA in BD vs. HC along 29 out of 43 WM 
tracts and whole skeleton FA (see Table 2, Figure 1). The largest effect sizes were found in 
the whole corpus callosum (CC) (R2 = 0.0441; P < 1.0      × 10-20), followed by the body (R2 = 
0.0368; P < 1.0      × 10-20) and genu (R2 = 0.0331; P < 1.0      × 10-20) of the CC and the 
bilateral cinguli (right: R2 = 0.0281; P < 1.0      × 10-20; left: R2 = 0.0269; P < 1.0      × 10-20). 
Notably, we found lower FA in bilateral tracts, with the exception of the inferior fronto-
occipital fasciculus, where significant difference was observed only in the right hemisphere. 
In a second analysis, with similar LMM but also      covarying for average FA, we still 
observed lower FA in BD vs. HC across 19 tracts, meaning that the whole-brain average FA 
moderately influenced the results and that the effects were not exclusively driven by a global 
decrease in FA in patients (Table S6).  
**** INSERT TABLE 2 HERE **** 
**** INSERT FIGURE 1 HERE **** 
Age and sex effects 
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To examine differential effects of age and sex on group differences in FA values, we tested 
for age-by-diagnosis and sex-by-diagnosis interactions for each ROI. Results showed 
significant age-by-diagnosis interactions in bilateral superior corona radiata, the posterior 
limb of the internal capsule and left cingulum, such that there was steeper apparent age-
related decline in the HC than BD group in all but the cingulate gyrus portion of the 
cingulum, where the opposite was found      (Table S7; Figure S1). We did not find any 
significant sex-by-diagnosis interaction (Table S8).  
Effects of clinical variables 
Within the BD group, we found a significant positive relationship of age at onset to FA in the 
right inferior fronto-occipital fasciculus (Table S9) and a negative association between illness 
duration and FA within the left cingulum (Table S10) (Figure S2). In addition, we observed 
significantly lower FA in patients receiving vs. not receiving antipsychotics within the genu 
of the CC and in patients receiving vs. not receiving anticonvulsants within multiple ROIs 
(Figures S3 and S4; Tables S11 and S12). In contrast, we found higher FA values in several 
regions among patients receiving vs. not receiving lithium (Figure S5, Table S13). 
We did not observe any significant relationships between FA and antidepressant medication, 
illness severity, history of psychotic symptoms, or BD subtype (I or II) (see Tables S14 to 
S17). 
Meta-analysis 
     Results from the meta-analysis revealed lower FA among 23 out of the 44 ROIs (43 tracts 
and the whole brain skeleton) analyzed (Table 3, Figure 2). Similarly to the mega-analysis, 
the results showed largest effect sizes for the whole CC (d = -0.46; P = 7.86 × 10-12), body of 
the CC (d = -0.43; P = 5.41 × 10-11) and left cingulum (d = -0.39; P = 2.38 × 10-8). Overall, 
the meta-analysis showed similar effects to the mega-analysis but was slightly      less 
sensitive. The I2 test indicates small to high heterogeneity across sites for all effect sizes 
13 
(I2=0.002–69.24). To allow comparison with other DTI studies of the ENIGMA consortium, 
we also conducted a meta-analysis based on bilateral tracts (i.e., 25 ROIs). We found 
significant decrease FA in patients with BD compared to HC along 15 fasciculi. Similarly, 
the higher effect sizes were observed for the CC (d = -0.46; P = 7.86 × 10-12) and cingulum (d 
= -0.39; P = 4.58 × 10-8)  (Figure S6, Table S18).  
**** INSERT TABLE 3 HERE **** 
**** INSERT FIGURE 2 HERE **** 
Discussion 
In the largest multi-center DTI study of BD to date, we found alterations of WM 
microstructure in patients with BD along multiple bundles, with      strongest effects      within 
the CC and the cingulum. FA was lower in patients in most ROIs, although      effect sizes 
were small. Age, age of onset, illness duration as well as anticonvulsants and antipsychotic 
medications were associated with lower FA. 
We collected individual data from 1,482 patients and 1,551 controls across 26 international 
cohorts, allowing a sample size considerably exceeding all prior      DTI studies of      BD. 
Unlike most studies that found localized WM alterations in BD, we identified widespread 
abnormalities (lower      FA along 29 out of the 44 regions analyzed in the mega-analysis and 
32 out of 44 ROIs in the meta-analysis). Similarly to results in the ENIGMA DTI 
schizophrenia project, this suggests a global profile of microstructural abnormalities      in 
BD, which are      however not specific to that disorder [25].  
For both analyses (i.e., mega and meta), the largest       effect sizes were observed within the 
CC and cingulum. This is consistent with a recent meta-analysis showing decreased FA 
within the CC,      cingulum and the anterior superior longitudinal fasciculus in BD in 
comparison to controls [29]. The cingulum is a major pathway in the limbic system. 
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Impairment of cingulum and uncinate structural integrity is in good agreement with previous 
models of altered fronto-limbic connectivity in BD [3,30].   
In contrast, the role of the CC in pathophysiological models of BD is less straightforward. 
Disconnection in patients with BD with psychotic history has been suggested [12] but there is 
no clear evidence for the implication of the CC in emotion processing or mood switching 
[31]. Reduced FA within the CC was also reported in a meta-analysis of DTI studies in 
schizophrenia [25] and major depressive disorder [29], suggesting an overlapping 
involvement in both psychosis and affective disorders. Further studies are warranted to 
evaluate to what      extent the CC is differentially affected in these disorders. Preliminary 
data suggest that disruption of inter-hemispheric connectivity is a disease marker rather than 
a vulnerability marker to BD [32]. Nonetheless, we identified extensive WM abnormalities 
suggesting that current pathophysiological models of BD are incomplete. Future models 
should not be limited to fronto-limbic networks, and should perhaps consider 
interhemispheric disconnectivity as a key feature of BD. 
Importantly, the      patient      group was significantly older than the control group. Although 
we controlled for age in all analy     ses, it is possible that the linear models used are not fully 
accounting for the age-related variance [33]. However, the assessment of the effects of age 
revealed a significant interaction between age and diagnosis      for only 4 ROIs out of the 43 
analyzed. We found a significant increase in      the effect of age in patients with BD for the 
left CGC only, while we found the reverse association for the bilateral SCR and the left 
PLIC, which is difficult to interpret. 
We found that lithium intake was associated with higher FA in several tracts, as well as with 
global FA. Prior      studies have suggested neuroprotective effects of lithium, on grey matter 
[23,34-36] and white matter [37]. Higher FA associated with lithium use could reflect a direct 
influence of lithium on water diffusion or a beneficial effect on myelination [38], as 
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suggested by the observation that lithium promotes myelin gene expression, morphological 
maturation, and remyelination in cultured oligodendrocytes via the Wnt/β-catenin and the 
Akt/CREB pathways [39].           In patients with BD, lithium may      increase      axial 
diffusivity in WM tracts also influenced by genetic variation in this pathway [22].  We also 
found lower FA in patients who received anticonvulsants in several tracts and average global 
FA. Further, patients who were on antipsychotic treatment showed lower FA within the genu 
of the CC. This is consistent with prior      results suggesting a negative relationship between 
anticonvulsants, antipsychotics and cortical thickness or FA [23,37]. However, it could be 
possible that the choice of the medication was driven by some patients’ particularities or 
unknown neurobiological characteristics, which are hard to assess with a cross-sectional 
design, leading to confounding by indication     . Longitudinal clinical trials are needed to 
clarify this point. 
We did not fi     nd significant differences between BD type I and type II. The power of 
previous meta-analyses of DTI studies has also been      too low     to perform this 
comparison. However, sensitivity analyses for      these meta-analyses indicated that the sub-
group of patients with BD I was driving the FA difference observed between patients with 
BD and HC [19,29,40]. Although we had enough power, the comparison of BD I vs. BD II 
did not      replicate this result. Consistent      with our results, however, ENIGMA analyses of 
T1-weighted anatomical MRI data of patients with BD did not yield any detectable      
differences between BD types (Hibar 2016 & 2018).    
In sum, the multi-site nature of the study is a strength that allowed us to detect small but 
significant differences. Our results seem to challenge the hypothesis of a precise localization 
for      the white matter alterations in BD. Indeed, we have highlighted extensive 
abnormalities, which      do not seem to be specific to this psychiatric disorder. Decreased FA 
across multiple bundles has already been      consistently observed in studies of schizophrenia, 
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with apparently higher effect sizes (e.g., Kelly et al., 2017).       Consequently,      to build 
more precise neurobiological models of BD future studies should benefit from new advanced 
neuroimaging methods such as Neurite Orientation Dispersion and Density Imaging (NOD     
DI) [41]. This recent processing model allows fine-     grained measurement of the WM 
microstructure, with physiological interpretation of the derived indices, and has already 
shown promising results in BD [42]. However, the large-scale application of such methods 
will only be possible with raw data sharing within international consortia. This will allow the 
application of advanced DTI models and whole-brain analyses, which are needed to better 
understand      WM abnormalities observed in BD. Finally, longitudinal studies conducted in 
conjunction with advanced DTI protocols are essential to clarify the impact of pharmaceutical 
treatments on brain microstructure. 
 
Some limitations are important to emphasize. We did not include other diffusion parameters 
in our analysis. Lower FA may represent abnormal fiber coherence but does not yield           
information on      fiber density or      myelination. The mean, radial and axial diffusivity 
measure would have added complementary information regarding the nature of WM 
alteration. However, we have focused on the most commonly used measure, which offers 
better comparability with prior      studies. Also, most studies have highlighted a correlation 
between FA and these other measures, while their inclusion would have tripled the number of 
analyses. In addition, although we found "widespread" WM abnormalities in patients with 
BD,       the robust ENIGMA DTI pipeline      used to partition the ROIs involved only long 
and isolinear bundles. With this methodological approach (i.e., FSL TBSS), we can     not 
evaluate localized changes within the superficial WM, as have been      previously observed in 
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crossings     , which may have led to incomplete      localization of group      differences. 
Further studies are warranted to identify more fine-grained WM abnormalities      in BD.  
Importantly, retrospective multi-site analyses have some limitations.      Differences in the 
acquisition parameters, magnet strength, head coil and manufacturer provided software could 
have impacted the results. However, we believe that our approach, using a harmonized data 
processing pipeline, with a reliable procedure, allows for the first time coordinated mega- and 
meta-analyses with robust results. 
Moreover, the effects of the covariates found here are only derived from post hoc analyses in 
cross-sectional studies with a somewhat limited representation of individuals with BD over      
age      50 (only 18% of the sample). Longitudinal studies would be more suitable to identify 
and predict the effect of age, illness duration/severity and medication on WM microstructure 
in patients with BD. In addition, despite their importance, we were not able to test the relation 
between FA and other covariates, such as the body mass index and frequent BD 
comorbidities (e.g., anxiety or substance use disorder). Too few sites had collected these 
measures to allow robust analyses. However, we believe that our sample is ecologically valid 
and captures the heterogeneity of BD.  
With this unprecedented sample size, we found evidence for widespread WM abnormalities 
in patients with BD and showed      differences in BD WM microstructure that were 
unobserved until now. These results may inform future DTI studies with regard      to 
expected effect sizes, and the effects of several      covariates and clinical variables. We also 
highlighted that the CC and the cingulum had the strongest decrease in FA in patients with 
BD. Despite      growing evidence for altered structure of the CC in BD, its specific role in the 
pathophysiology of BD needs to be further integrated into neural models of BD.  
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Figures  
 
Figure 1. Results of the mega-analysis. A) Effect sizes of fractional anisotropy (FA) 
differences between patients with bipolar disorder (BD) and healthy controls projected on the 
43 white matter (WM) tracts analyzed. B) R squared (effect size) with confidence interval, 
sorted in increasing order of      magnitude, for the regions showing significant differences 
between bipolar patients and healthy controls. 
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Figure 2. Results of the meta-analysis. A) Effect sizes for      fractional anisotropy (FA) 
differences between patients with bipolar disorder (BD) and healthy controls projected on the 
43 white matter (WM) tracts analyzed. B) Cohen’s d (effect size) sorted in increasing order of      
magnitude for significant differences between bipolar patients and healthy controls. 
Significant findings after Bonferroni correction are highlighted in blue. Error bars represent 
standard error. 
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Tables 
 
Table 1. Descriptive statistics of sample 
 Bipolar Disorder Healthy Controls   
 Na mean / freqb std N
a
 
mean / 
freqb std t / χ2 p-value 
Mean Age 1482 39.60 12.15 1551 35.08 12.10 10.11 <0.001 
Sex (% females) 1482 60.66% 
 
1551 51.13% 
 
25.77 <0.001 
Age of Onset 1046 25.19 10.35 
     
Illness Duration 1045 15.47 10.58 
     
Depression Score 
        
HDRS-17 115 8.63 8.29      
HDRS-21 285 6.42 8.06      
MADRS 230 9.45 9.79      
Number of 
depressive 
Episodes 
587 5.84 6.02 
     
Mania Score 
(YMRS) 545 2.80 3.93 
     
Number of manic 
Episodes 485 4.30 5.44 
     
Total number of 
major Episodes 476 10.45 10.15 
     
Density of 
Episodesc 414 0.82 1.00 
     
On Medication 904 84.62% 36.09% 
     
Antipsychotics 862 45.82% 49.85% 
     
Antidepressants 903 31.34% 46.41% 
     
Anticonvulsants 812 39.29% 48.87% 
     
Lithium 824 42.48% 49.46% 
     
History of 
psychotic 
symptoms 
908 54.30% 49.84% 
     
Lifetime alcohol 
abuse 272 8.09% 27.32% 
     
Onset Timed         
Early 334 31.93%       
29 
Intermediate 534 51.05%       
Late 178 17.02%       
BD Type         
BD1 432 77.01%       
BD2 129 22.99%       
Mood Phase         
Depressed 313 46.23%       
Euthymic 336 49.63%       
Hypomanic 2 0.30%       
Manic 18 2.66%       
Mixed 8 1.18%       
a
 Number of available data 
b
 Proportion calculated among the available data 
c
 Density = Total episodes / Illness duration  
d
 Early: < 18 yrs ; 18 yrs < Intermediate < 35 yrs ; Late: > 35 yrs  
30 
Table 2. Mega-analysis results: Linear mixed model parameters sorted by effect size 
(descending order) for FA differences between bipolar patients and healthy controls after 
controlling for age and sex. 
ROI β s.e. t-value Pcorr>|t| R2 [0.025 0.975] Sign. 
Projection fibers        
PTR.R 0.0098 0.0013 7.3542 1.09E-11 0.0176 0.0095 0.0281 *** 
PTR.L 0.0079 0.0013 5.9150 1.63E-07 0.0115 0.0051 0.0203 *** 
ACR.L 0.0065 0.0011 5.8177 2.91E-07 0.0110 0.0048 0.0197 *** 
CR.L 0.0046 0.0009 5.2310 7.94E-06 0.0088 0.0034 0.0168 *** 
ACR.R 0.0056 0.0011 4.9348 3.73E-05 0.0080 0.0029 0.0156 *** 
CR.R 0.0040 0.0009 4.6037 1.90E-04 0.0068 0.0022 0.0140 *** 
PCR.R 0.0040 0.0011 3.8079 6.29E-03 0.0048 0.0011 0.0110 ** 
ALIC.L 0.0040 0.0011 3.7958 6.61E-03 0.0047 0.0011 0.0108 ** 
ALIC.R 0.0038 0.0010 3.6899 1.00E-02 0.0044 0.0009 0.0104 * 
PCR.L 0.0036 0.0010 3.4692 2.33E-02 0.0040 0.0007 0.0098 * 
SCR.L 0.0028 0.0010 2.7731 2.46E-01 0.0026 0.0002 0.0075 NS 
SCR.R 0.0022 0.0010 2.3003 9.46E-01 0.0017 0.0000 0.0060 NS 
IC.L 0.0014 0.0008 1.6965 1.00E+00 0.0009 0.0000 0.0044 NS 
RLIC.L 0.0014 0.0011 1.3106 1.00E+00 0.0006 0.0000 0.0036 NS 
IC.R 0.0011 0.0008 1.3451 1.00E+00 0.0006 0.0000 0.0036 NS 
CST.R -0.0021 0.0016 -1.2829 1.00E+00 0.0005 0.0000 0.0035 NS 
CST.L -0.0017 0.0017 -1.0213 1.00E+00 0.0003 0.0000 0.0030 NS 
RLIC.R 0.0009 0.0012 0.7712 1.00E+00 0.0002 0.0000 0.0025 NS 
PLIC.L -0.0007 0.0010 -0.7363 1.00E+00 0.0002 0.0000 0.0024 NS 
31 
PLIC.R -0.0002 0.0010 -0.2474 1.00E+00 0.0000 0.0000 0.0018 NS 
Association fibers        
CGC.R 0.0136 0.0015 9.3757 0.00E+00 0.0281 0.0176 0.0408 *** 
CGC.L 0.0138 0.0015 9.1811 0.00E+00 0.0269 0.0166 0.0395 *** 
EC.L 0.0057 0.0009 6.0965 5.39E-08 0.0119 0.0054 0.0209 *** 
EC.R 0.0051 0.0009 5.6114 9.65E-07 0.0100 0.0042 0.0184 *** 
UNC.R 0.0103 0.0019 5.3636 3.87E-06 0.0096 0.0039 0.0178 *** 
UNC.L 0.0103 0.0020 5.1902 9.87E-06 0.0090 0.0035 0.0171 *** 
SS.L 0.0054 0.0012 4.6913 1.25E-04 0.0072 0.0024 0.0146 *** 
IFO.R 0.0080 0.0017 4.6490 1.53E-04 0.0071 0.0024 0.0144 *** 
SFO.R 0.0057 0.0013 4.2623 9.18E-04 0.0060 0.0017 0.0128 *** 
SFO.L 0.0053 0.0014 3.8511 5.29E-03 0.0049 0.0012 0.0112 ** 
FX.ST.R 0.0047 0.0014 3.3251 3.94E-02 0.0036 0.0006 0.0092 * 
IFO.L 0.0059 0.0018 3.2375 5.36E-02 0.0035 0.0005 0.0090 NS 
SS.R 0.0039 0.0012 3.1308 7.75E-02 0.0032 0.0004 0.0086 NS 
FX.ST.L 0.0038 0.0013 2.9044 1.63E-01 0.0028 0.0003 0.0078 NS 
CGH.R 0.0038 0.0019 2.0100 1.00E+00 0.0013 0.0000 0.0052 NS 
CGH.L 0.0007 0.0018 0.3830 1.00E+00 0.0000 0.0000 0.0019 NS 
Commissural fibers        
CC 0.0123 0.0010 11.9431 0.00E+00 0.0441 0.0308 0.0594 *** 
BCC 0.0150 0.0014 10.7856 0.00E+00 0.0368 0.0247 0.0511 *** 
GCC 0.0123 0.0012 10.2936 0.00E+00 0.0331 0.0217 0.0468 *** 
SCC 0.0077 0.0009 8.1690 1.95E-14 0.0209 0.0119 0.0322 *** 
FX 0.0185 0.0025 7.4763 4.42E-12 0.0184 0.0101 0.0292 *** 
AverageFA 0.0025 0.0006 4.0044 2.80E-03 0.0050 0.0012 0.0113 ** 
32 
*pcorr<0.05; **pcorr<0.01; ***pcorr<0.001; ns: not significant  
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Table 3. Meta-analysis results: Cohen’s d values, their s.e., P-values and I2 values 
(heterogeneity between sites) sorted by effect size (descending order) for FA differences 
between patients with bipolar disorder and healthy controls after controlling for age and sex. 
ROI Cohen’s d s.e. p-value I2 p-value (corr) Sign. 
Projection fibers      
ACR.L -0.245 0.048 3.14E-07 25.562 8.86E-06 *** 
ACR.R -0.217 0.051 2.07E-05 33.382 1.03E-03 ** 
CR.L -0.202 0.053 1.32E-04 37.861 4.00E-03 ** 
CR.R -0.180 0.056 1.26E-03 43.697 2.60E-02 * 
ALIC.L -0.158 0.056 4.41E-03 43.311 2.32E-01 NS 
PCR.R -0.152 0.043 4.26E-04 12.031 1.13E-01 NS 
PCR.L -0.136 0.055 1.37E-02 42.736 7.39E-01 NS 
ALIC.R -0.131 0.048 6.52E-03 26.872 2.78E-01 NS 
SCR.L -0.095 0.052 6.90E-02 36.840 1.00E+00 NS 
SCR.R -0.072 0.061 2.36E-01 53.242 1.00E+00 NS 
IC.L -0.070 0.055 2.01E-01 41.932 1.00E+00 NS 
IC.R -0.058 0.054 2.75E-01 39.437 1.00E+00 NS 
RLIC.R -0.047 0.055 3.90E-01 41.619 1.00E+00 NS 
RLIC.L -0.044 0.055 4.21E-01 41.598 1.00E+00 NS 
CST.L -0.012 0.065 8.49E-01 58.035 1.00E+00 NS 
CST.R 0.012 0.062 8.50E-01 53.890 1.00E+00 NS 
PLIC.L 0.031 0.053 5.60E-01 37.920 1.00E+00 NS 
PLIC.R 0.034 0.044 4.35E-01 13.722 1.00E+00 NS 
Association fibers      
34 
CGC.L -0.391 0.062 2.99E-10 53.489 2.38E-08 *** 
CGC.R -0.350 0.057 7.50E-10 45.173 2.00E-06 *** 
EC.L -0.233 0.049 1.65E-06 27.203 1.06E-04 *** 
UNC.L -0.231 0.052 8.16E-06 35.172 3.30E-04 *** 
SS.L -0.220 0.044 6.96E-07 15.563 5.59E-05 *** 
UNC.R -0.219 0.049 8.05E-06 28.252 1.30E-03 ** 
EC.R -0.205 0.042 1.09E-06 8.287 2.58E-04 *** 
IFO.R -0.180 0.047 1.19E-04 22.441 3.99E-03 ** 
IFO.L -0.145 0.039 2.24E-04 0.000 1.41E-02 * 
FX.ST.R -0.145 0.045 1.43E-03 18.610 9.68E-02 NS 
SFO.L -0.144 0.051 4.67E-03 33.405 2.00E-01 NS 
SS.R -0.140 0.053 8.63E-03 39.037 3.17E-01 NS 
FX.ST.L -0.134 0.039 6.40E-04 0.002 5.12E-02 NS 
SFO.R -0.127 0.053 1.65E-02 38.320 7.26E-01 NS 
CGH.R -0.080 0.045 7.69E-02 18.794 1.00E+00 NS 
CGH.L -0.039 0.044 3.71E-01 14.618 1.00E+00 NS 
Commissural fibers      
CC -0.462 0.055 5.08E-17 41.305 7.86E-12 *** 
BCC -0.430 0.052 2.32E-16 35.479 5.41E-11 *** 
GCC -0.373 0.066 1.78E-08 59.395 6.87E-06 *** 
SCC -0.339 0.053 1.97E-10 37.906 5.66E-08 *** 
FX -0.288 0.054 8.19E-08 39.029 7.84E-05 *** 
AverageFA -0.260 0.076 5.69E-04 69.240 1.66E-01 NS 
*pcorr<0.05; **pcorr<0.01; ***pcorr<0.001; ns: not significant 
 
